compared

Novo Nordisks oral semaglutide 25 mg (Wegovy in a pill*) delivered 16.6% weight loss in people with obesity in a newly published study

Oral semaglutide 25 mg (the once-daily pill formulation of Wegovy®) achieved significant weight loss, with one in three study participants…

4 weeks ago

Rezolve Ai Gains Powerful Institutional Backing as Market Undervaluation Becomes Clear

Citadel, BlackRock, Vanguard, Jane Street, Northern Trust, Man Group, and State Street amongst others take positions as institutional ownership surpasses…

1 month ago

Encaleret Showed Parathyroid Hormone-Independent Normalization of Blood and Urine Calcium in Phase 2 Proof-of-Concept Study in Post-Surgical Hypoparathyroidism

September 06, 2025 14:30 ET  | Source: BridgeBio Pharma, Inc. - 80% of post-surgical hypoparathyroidism participants achieved concomitant blood and…

1 month ago

Medidata Secures a Leader Position in Everest Group’s PEAK Matrix Assessment for eCOA, Driving the New Patient Experience Forward

Medidata eCOA was the highest Leader recognized in the evaluation, supporting over 1M+ patients and reducing study build timeline by…

1 month ago

Kia America posts highest monthly sales in company history

Kia’s total sales in August reached 83,007 units, up 10.4 percent year-over-yearYear to date total sales are up 8.6 percent,…

1 month ago

GGVL Relaunches V21 in 100% Recycled PET — India’s First Beverage Brand to Do So

From turning waste into want, to reshaping what premium looks like — Great Galleon Ventures Limited sets a new benchmark…

1 month ago

Cytokinetics Presents New Data Related to Aficamten at the European Society of Cardiology Congress 2025

Additional Data from MAPLE-HCM Shows Aficamten Improves Cardiac Structure and Function Compared to Metoprolol; Simultaneous Publication in the Journal of the American…

2 months ago

Novo Nordisks Wegovy cuts risk of heart attack, stroke or death by 57% compared to tirzepatide in real-world study of people with obesity and cardiovascular diseas

Compared with tirzepatide, Wegovy® (semaglutide 2.4 mg) showed a significant 57% greater reduction in the risk of heart attack, stroke…

2 months ago

IMG Shares 2025 Autumn Travel Trends: Top Destinations and Increased Spending

IMG took a sample of its customers and reviewed more than 30,000 travel itineraries of members with upcoming travel plans…

2 months ago

Novo Nordisk A/S: Wegovy approved in the US for the treatment of MASH

Bagsværd, Denmark, 15 August 2025 – Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved an…

2 months ago